Novartis Femara Adds Extended Adjuvant Breast Cancer Treatment Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Femara is the first treatment option for women who have completed five years of tamoxifen therapy following surgery, Novartis says. Approval of new indication follows release of study data in October 2003.
You may also be interested in...
Novartis To File Femara Early Adjuvant NDA In Second Quarter
The company will release topline data from a pivotal study of letrozole in early adjuvant treatment of breast cancer Jan. 26. Femara sales grew 62% in 2004 to $386 mil.; Novartis expects the aromatase inhibitor will reach $1 bil. in sales by 2008.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability